Molecular mechanism of Compound Qingdai Capsule in the treatment of psoriasis based on network pharmacology and molecular docking

Objective:Although Compound Qingdai Capsule(CQC)successfully treats psoriasis,the exact mechanism remains unclear.Our research used network pharmacology to investigate the molecular mechanism of CQC in treating psoriasis.Methods:The Traditional Chinese Medicine Systems Pharmacology platform was used to screen the bioactive chemical elements and identify gene targets,and the ingredient-target network was visualized by Cytoscape software.Genes associated with psoriasis were found in the Gene Expression Omnibus database.The protein-protein interaction network was created using STRING and Cytoscape,and the hub genes were identified using MCODE and topological analysis.Gene ontology and Kyoto encyclopedia of genes and genomes analyses were applied to obtain hub genes’biological processes and signaling pathways.Subsequently,the ingredient-target-pathway-disease network was visualized by Cytoscape.Results:Finally,an active ingredient-target network of CQC containing 130 active ingredients and 213 targets was built.Conclusion:The top 3 bioactive components were identified as quercetin,luteolin,and kaempferol,and the top 5 hub genes were identified as IL1B,CXCL8,STAT3,MMP9,and HMOX1.The critical pathways of CQC treatment in psoriasis were AGE-RAGE signaling,IL-17 signaling,TNF signaling,Fluid shear stress and atherosclerosis,and Toll-like receptor signaling pathway.Molecular docking confirmed a robust binding affinity between the main active ingredients of CQC with the hub target proteins.On this basis,additional animal or cellular research might be undertaken to investigate the targets and mechanisms of CQC treatment in psoriasis.

Quality Standard of Compound Quanchangning Capsule

[ Objective] The research aimed to study the quality standard of Compound Quanchangning Capsule. [ Method] Coptis, Phelledendron, Pulsatilla and Astragalus in Compound Quanchangning Capsule were indentified qualitatively by thin layer chromatography （ TLC）, and the content of berberine hydrochloride was determined by high performance liquid chromatography （HPLC）, to study the quality standard of Compound Quanchangning Capsule. [ Result] TLC identification showed that the tested product was clear and well-separated with no interference. Berberine hydrechloride showed a good linear relationship with peak area at the injection volume of 10.92 - 163.74 ~Lg/mL, and the regression equation was Y = 39 611X -2 387. 9 （R2 = 0. 999 8） ; the average recovery was 97.60%, and the relative standard deviation was 1.64% （n =6）. [ Conclusion] The standard is simple in operation and good in specificity, stability and repeatability, which is prompted as a favorable method for quality control of Compound Quanchangning Capsule.

Meta-analysis and Trial Sequential Analysis of Compound Qingdai Capsule in the Treatment of Psoriasis

[Objectives]To analyze the efficacy of Compound Qingdai Capsule in the treatment of psoriasis and conduct a systematic evaluation.[Methods]The clinical total effective rate,PASI index score,IL-17 level,IL-23 level,TNF-level,and adverse reactions were analyzed.TSA 0.9 software was used to conduct sequential analysis of the total effective rate,and subgroup analysis was performed according to the average age of the experimental group.[Results]Single application of Compound Qingdai Capsule or in combination with other methods in the treatment of psoriasis was superior to non-Compound Qingdai Capsule group,and the side effects were less than non-Compound Qingdai Capsule group;the n≥40 year-old group had certain heterogeneity,suggesting that the difference was statistically significant,and the effective rate was higher than that of the control group.The funnel plot showed that the graph was asymmetrical,and there may be publication bias or the possibility of low-quality literature.The TSA results indicated that the actual sample size was far lower than the expected sample size,and the cumulative Z value did not reach the TSA cut-off value and more trials need to be included to confirm the efficacy.[Conclusions]Compound Qingdai Capsule has a clear curative effect on psoriasis,and its safety is high.This study can provide relevant evidence for the effectiveness of Chinese patent drugs(CPD)in treating psoriasis.

Validation of Microbial Limit Test Methods of Compound Gangbangui Capsule

[Objectives] This study was conducted to establish a method for microbial limit test of Compound Gangbangui Capsule. [Methods] According to the Chinese Pharmacopoei 2015 edition of the four general rules,the microbiological limits of non-sterile products were verified. [Results]Compound Gangbangui Capsule has a strong inhibitory effect on S. aureus,and the antimicrobial activity was significantly eliminated after increasing the diluent（ 1∶ 20）; and the recoveries were in the range of 0. 5-2. 0 when the total quantities of aerobic microbes were determined by dilution method（ 1∶ 20）. When the total quantities of mould and yeast were determined by conventional method（ 1∶ 20）,the recoveries were from 0. 5 to 2. 0,and Escherichia coli can be detected in experimental groups by the test solution dilution method. [Conclusions]With the plate method,the total quantities of aerobic bacteria and the quantities of mould and yeast were examined by increasing diluent and conventional method,respectively,and control bacteria,E. coli was examined by conventional method. This method has been proved effective for microbial limit test of Compound Gangbangui Capsule,and can effectively control the quality of the preparation. The method is accurate and reliable.

Clinical Effect of Laser Treatment Combined with Compound Xueshuantong Capsule in the Treatment of Diabetic Retinopathy

Objective:To determine the clinical value of compound Xueshuantong capsule in the treatment of diabetic retinopathy on the basis of laser treatment.Methods:Data were collected from 98 patients with diabetic retinopathy from February 2021 to February 2022.They were divided into two groups by drawing lots.The experimental group was treated with compound Xueshuantong capsule and laser treatment,whereas the control group was treated with laser treatment alone.Results:The absorption of exudation,resolution of retinal edema,and absorption of bleeding took longer in the control group;the incidence of visual acuity recovery to more than 0.5 and the patients’blood glucose levels were better in the experimental group,p<0.05.Conclusion:For patients with diabetic retinopathy,laser treatment combined with compound Xueshuantong capsule can effectively improve the visual function and rehabilitation efficiency of patients with diabetic retinopathy as well as stabilize their blood sugar levels.It has high clinical application value.

Experimental Study on the Repair Effect of Xianlinggubao Capsule on Osteoporotic Vertebral Compression Fracture in Rabbits

[Objectives]To observe the effect of Xianlinggubao Capsule on osteoporotic vertebral compression fracture(OVCF)in rabbits and the influence mechanism of the repair of fractures.[Methods]Female June age 30 rabbits were randomly divided into control group,model control group and Xianlinggubao group.After bilateral ovariectomy,the model control group and Xianlinggubao group were injected with dexamethasone continuously for 4 weeks,and then the OVCF compound model was established by surgery.The Xianlinggubao group was treated with Xianlinggubao at a dose of 300 mg/(kg·d)for 60 d,while the blank control group and the model control group were treated with the same amount of normal saline for 60 d.The number of blood vessels and the expression of bone morphogenetic protein-2(BMP-2)were detected by immunohistochemical staining and the bone mineral density(BMD)in the callus of the third lumbar fracture area of rabbits was measured.The content of serum phosphorus(P),alkaline phosphatase(ALP)and total calcium(TCa)in rabbit venous blood were measured by automatic biochemical analyzer.The content of vascular endothelial growth factor(VEGF)and platelet-derived growth factor(PDGF)in rabbit venous blood were measured by ELISA kit.[Results]The number of blood vessels and the expression of BMP-2 in the callus of the third lumbar fracture area of rabbits was high in Xianlinggubao group,the content of serum P,ALP,TCa,VEGF and PDGF was obviously increased,BMD was obviously increased,the bone microstructure of the third lumbar vertebrae fracture area of rabbits was basically restored.Compared with the model control group(P<0.05),the difference was statistically significant.[Conclusions]Xianlinggubao Capsule can increase calcium and phosphorus deposition,promote the formation of blood vessels in the fracture area of OVCF in rabbits,and have a strong repair effect on OVCF in rabbits.

灵芝螺旋藻复方胶囊辅助降血糖功能

该文探究灵芝螺旋藻复方胶囊对Ⅱ型糖尿病小鼠的降血糖作用。采用高热能饲料结合腹腔注射链脲佐菌素的方法,建立Ⅱ型糖尿病小鼠模型,随机将小鼠分为对照组、模型组和低、中、高剂量组。灵芝螺旋藻复方胶囊连续干预4周,测定小鼠体质量、脏器指数、血液相关指标并观察肝、胰腺、盲肠病理组织切片。结果显示,低、中、高剂量(相当于人体推荐用量5、10、30倍)灵芝螺旋藻复方胶囊能不同程度改善糖尿病小鼠脏器指数、血糖水平以及葡萄糖耐量;从病理组织切片观察到经过3个剂量组干预的肝细胞体积明显恢复且排列整齐、脂滴空泡减少,肝细胞的损伤与炎症明显改善;胰岛细胞边界随剂量的增大而变得逐渐清晰且有序;低、中剂量两个组除绒毛有少部分呈圆状环绕外,3个剂量组盲肠组织外膜、肌层、黏膜、绒毛形态均有明显改善。综上,低、中、高3个剂量灵芝螺旋藻复方胶囊均可有效改善Ⅱ型糖尿病小鼠的糖脂代谢,有助于维持血糖健康水平。

复方红豆杉胶囊维持治疗气虚痰瘀证晚期非小细胞肺癌的多中心、大样本、前瞻性队列研究

目的:探讨复方红豆杉胶囊维持治疗气虚痰瘀证晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的临床疗效和安全性。方法:采用多中心、大样本、前瞻性队列研究方法,纳入一线化疗4~6周期后疗效评价疾病稳定以上进入维持治疗阶段患者,根据患者意愿分为治疗组160例,对照组109例。对照组根据鳞癌和非鳞癌分别给予吉西他滨和培美曲塞单药化疗维持治疗,治疗组给予复方红豆杉胶囊维持治疗。均以21天为1个疗程,两组干预至少2个疗程,每周期进行生活质量评价,每2疗程进行影像学疗效评价。比较两组疾病无进展生存时间(progression-free survival time,PFS)、生活质量,同时进行药物安全性评价。结果:269例入组患者中,246例患者出现PFS终点事件(91.45%),其中治疗组145例,中位PFS为106天,对照组101例,中位PFS为120天,两组PFS比较差异无统计学意义(P>0.05)。采用美国肺癌生存质量量表(FACT-L4.0版)和欧洲五维健康量表中视觉模拟量表(EQ-5D-VAS)对两组患者生活质量评分进行比较,两种生活质量评价量表均提示治疗组较对照组在提高生活质量方面存在优势(P<0.05)。治疗期间两组共有19例患者出现ADR,治疗组7例(占治疗组人数4.38%),对照组12例(占对照组人数11.01%),ADR发生率在治疗组中更低,尤其表现在骨髓抑制不良反应的发生率方面。结论:在延长PFS方面,复方红豆杉胶囊维持治疗气虚痰瘀证晚期NSCLC的疗效非劣于现代医学单药维持化疗,且在高生活质量、低不良反应方面,复方红豆杉胶囊更具有一定优势。

温针灸联合复方雪莲胶囊治疗强直性脊柱炎对软骨代谢和炎性反应的影响

目的探讨温针灸联合复方雪莲胶囊治疗强直性脊柱炎对软骨代谢和炎性反应的影响。方法选取医院2020年6月至2022年6月收治的强直性脊柱炎患者178例,按治疗方案的不同分为对照组和观察组,各89例。两组患者均予温针灸治疗,观察组患者加服复方雪莲胶囊。两组均连续治疗2个月。结果观察组总有效率为95.51%,显著高于对照组的85.39%(P<0.05)。两组患者治疗后的巴氏强直性脊柱炎疾病活动指数(BASDAI)评分、巴氏强直性脊柱炎功能指数(BASFI)评分、视觉模拟量表(VAS)评分均显著降低,枕墙距、指地距均显著缩小,腰椎活动度均显著改善,血清软骨寡聚基质蛋白、白细胞介素35、肿瘤坏死因子-α、C反应蛋白、白细胞介素2及白细胞介素17的表达水平均显著降低,且观察组改善程度更显著(P<0.05)。观察组患者治疗后的腰背疼痛、关节水肿、关节疼痛、晨僵缓解时间均显著短于对照组(P<0.05)。观察组不良反应发生率为4.49%,显著低于对照组的10.11%(P<0.05)。结论温针灸联合复方雪莲胶囊治疗强直性脊柱炎,能有效缓解患者的临床症状,减轻关节疼痛,抑制炎性反应,降低血清炎性因子表达水平。

复方万年青胶囊联合化疗对中晚期非小细胞肺癌患者辅助性T细胞17/调节性T细胞失衡和血清凋亡因子的影响

目的 探讨复方万年青胶囊联合吉西他滨+顺铂(GP)化疗方案对中晚期非小细胞肺癌(NSCLC)患者辅助性T细胞17(Th17)/调节性T细胞(Treg)失衡和血清凋亡因子的影响。方法 选择2018年3月至2021年2月西安医学院第一附属医院收治的98例中晚期NSCLC患者。按照随机数字表法将患者分为对照组和观察组,各49例。对照组接受GP化疗方案治疗;观察组在对照组基础上联合复方万年青胶囊口服治疗。以21 d为1个疗程,完成4个疗程的化疗。比较2组临床疗效以及治疗前后血清Th17、Treg、Th17/Treg比值、肿瘤标志物水平、凋亡因子水平。观察2组治疗期间不良反应发生情况。所有患者随访2年,记录无进展生存期(PFS)和总生存期。结果 治疗后,观察组客观缓解率和疾病控制率均高于对照组(均P<0.05)。治疗后,2组Treg均低于治疗前、且观察组低于对照组[(2.9±0.5)%比(4.8±0.8)%],2组Th17、Th17/Treg比值均高于治疗前、且观察组均高于对照组[(1.42±0.13)%比(1.25±0.11)%、(0.49±0.10)比(0.26±0.08)](均P<0.05);2组癌胚抗原、细胞角蛋白19片段、糖类抗原125、B淋巴细胞瘤基因2(Bcl-2)水平均低于治疗前、且观察组均低于对照组,2组Bcl-2相关X蛋白水平均高于治疗前、且观察组高于对照组(均P<0.05)。2组治疗期间不良反应发生率比较差异无统计学意义(P>0.05)。观察组中位PFS、中位总生存期均长于对照组(均P<0.01)。结论 复方万年青胶囊联合GP化疗方案治疗中晚期NSCLC患者,可有效控制疾病进展,延长生存期,调节血清肿瘤标志物和血清凋亡因子水平,改善免疫功能。

“温阳祛瘀”中药熏洗联合复方益母草胶囊对阳虚血瘀型子宫复旧不全产妇早期康复的临床研究

目的:研究分析“温阳祛瘀”中药熏洗联合复方益母草胶囊对阳虚血瘀型子宫复旧不全产妇早期康复的临床效果。方法:前瞻性纳入2021年4月—2023年4月在广东省人民医院赣州医院妇产科住院的阳虚血瘀型子宫复旧不全产妇80例,将患者按照随机数字表法分为治疗组(n=40)和对照组(n=40)。对照组在常规治疗的基础上加用复方益母草胶囊,治疗组在对照组基础上加以“温阳祛瘀”中药熏洗治疗。比较两组临床症状消失时间、子宫恢复情况、疼痛情况、睡眠质量、心理状态、临床疗效。结果:治疗组恶露、腹痛消失时间均早于对照组,子宫底高度、子宫体积均小于对照组,子宫腔积液量少于对照组,视觉模拟评分法(VAS)、抑郁自评量表(SDS)、焦虑自评量表(SAS)、匹兹堡睡眠质量指数(PSQI)评分均低于对照组,临床疗效优于对照组,差异均有统计学意义(P<0.05)。结论:“温阳祛瘀”中药熏洗联合复方益母草胶囊能显著促进阳虚血瘀型子宫复旧不全产妇早期康复,有效提高产妇睡眠质量,改善不良情绪,整体治疗效果较佳。

羟丙基淀粉植物胶囊的研究

以羟丙基淀粉(HPS)为主料,羧甲基纤维素钠(CMC-Na)和海藻酸钠(SA)为增强剂,并辅以凝胶剂和塑化剂,制备了复合植物胶囊HPS/CMC-Na/SA,采用单因素实验和正交实验优化了制备工艺,并通过SEM、FTIR、XRD对其进行表征。结果表明,当HPS加量为85 mg·mL^(-1)、CMC-Na加量为8.5 mg·mL^(-1)、SA加量为4.5 mg·mL^(-1)时,复合植物胶囊的抗拉强度为30.08 MPa,断裂伸长率为14.49%,杨氏模量为1289.77 MPa,800 nm透光率为78.068%,400 nm透光率为63.072%。

复方血栓通胶囊治疗非增殖期糖尿病视网膜病变效果的Meta分析

目的系统评价复方血栓通胶囊治疗非增殖期糖尿病视网膜病变(NPDR)的效果。方法计算机检索中国知网、万方、维普、中国生物医学文献数据库(CBM)、Embase、PubMed和The Cochrane Library数据库(检索时间为建库至2022年4月),纳入复方血栓通胶囊治疗NPDR的随机对照研究。2位分析员独立筛选、阅读、提取文献资料并评价相关偏倚风险后,采用RevMan5.3软件进行Meta分析。结果共纳入8条文献,包括1048例患者。Meta分析结果显示,与对照组相比,试验组可显著提高患者的临床疗效[RR=1.27,95%CI(1.18,1.36),P<0.00001],减轻黄斑水肿[MD=-26.27,95%CI(-35.72,-16.83),P<0.00001],改善患者眼动脉血流动力学指标[MDPSV=1.10,95%CI(0.82,1.39),P<0.00001;MDEDV=0.73,95%CI(0.60,0.86),P<0.00001;MDRI=-0.02,95%CI(-0.03,-0.01),P<0.00001];试验组与对照组的视网膜中央动脉血流动力学指标无显著差异(P>0.05)。结论复方血栓通胶囊可显著提高NPDR患者的临床疗效、减轻黄斑水肿、改善眼动脉血流动力学指标,但对视网膜中央动脉血流动力学指标无显著改善作用。

基于网络药理学探讨复方斑蝥胶囊调控乳腺癌铁死亡的机制研究

目的本研究旨在通过网络药理学探讨复方斑蝥胶囊(CMC)调控乳腺癌(BC)铁死亡的可能靶标及作用机制。方法分别利用TCMSP、Swiss Target Prediction、GeneCards、FerrDb等数据库获得CMC、BC以及调控铁死亡的相关靶点。利用STING网站构建药物-疾病交集靶点的蛋白相互作用信息图(PPI)。运用Cytoscape软件构建生成药物-活性成分-作用靶点网络图,再进行KEGG和GO功能富集分析,并通过分子对接来模拟活性成分作用于靶蛋白的结合情况,最后通过GEPIA、HPA和cBioPortal数据库验证核心靶点在乳腺癌中的表达及突变情况。结果共获得198个活性化学成分,药物-疾病共同靶蛋白基因51个。PPI显示,关键靶点为TP53、IL6、EGFR、HIF1A、STAT3。主要活性成分为山奈酚、槲皮素、异鼠李素、常春藤皂苷元、β-谷甾醇。KEGG通路富集分析表明,主要涉及FoxO、NF-kappa B、Hippo等信号通路。分子对接结果表明,主要活性化合物与关键靶点均具有良好的结合活性。生物信息学结果表明,BC组织中IL6和EGFR的mRNA水平高表达,且TP53的预后价值差异有统计学意义(P<0.05)。cBioPortal工具显示,1756例患者中有658例(37.5%)存在基因突变。结论复方斑蝥胶囊可能通过多成分、多靶点、多途径的方式发挥调控铁死亡治疗BC的作用,为其临床应用提供参考依据。

基于网络药理学的复方血栓通胶囊治疗视网膜静脉阻塞机制研究

目的:基于网络药理学方法探究复方血栓通胶囊治疗视网膜静脉阻塞(retinal vein occlusion,RVO)的潜在作用靶点及机制。方法:利用中药系统药理学数据库与分析平台(traditional Chinese medicine systems pharmacology database and analysis platform,TCMSP)获取三七、黄芪、丹参、玄参的活性成分及相关靶点。运用GeneCards、在线孟德尔人类遗传数据库(online mendelian inheritance in man,OMIM)以及DrugBank数据库获取RVO的相关作用靶点,采用Cytoscape 3.7.2软件绘制“疾病-药物-活性成分-靶点”图,借助STRING数据库建立靶点蛋白-蛋白互作网络(protein-protein interactions,PPI),并挖掘其中潜在的蛋白质功能模块。最后通过Metascape平台进行基因本体论功能(gene ontology,GO)富集分析和京都基因与基因组百科全书(kyoto encyclopedia of genes and genomes,KEGG)富集分析。结果:筛选得到复方血栓通胶囊119个有效活性成分,有效靶点202个,RVO的疾病靶点1539个,最终获得复方血栓通胶囊治疗RVO有效靶点115个,通过PPI筛选出主要核心靶点10个,富集分析得到的有效靶点主要参与癌症相关通路,糖尿病并发症相关AGE-RAGE、流体剪切应力与动脉粥样硬化、白细胞介素17、肿瘤坏死因子、PI3K-Akt、MAPK等信号通路。结论:复方血栓通胶囊主要通过调节氧化应激、炎症因子、新血管生成、细胞凋亡等过程治疗RVO。

复方生脉成骨胶囊修复激素性股骨头坏死的作用机制

背景:复方生脉成骨胶囊治疗早期激素性股骨头坏死的疗效佳,但具体治疗机制尚不完全明确。目的:观察复方生脉成骨胶囊干预对激素性股骨头坏死大鼠骨组织中岩藻糖基转移酶8、成骨基因及Wnt/β-catenin信号通路蛋白表达的影响。方法:取60只雄性SD大鼠,采用随机数字表法分为空白组、模型组、中药低剂量组、中药中剂量组及中药高剂量组,每组12只。模型组和中药低、中、高剂量组通过皮下注射咪喹莫特(每2周一次,共2次)与臀肌注射甲强龙(1次/周,共4次)的方法建立激素性股骨头坏死模型,末次造模给药后第2天,中药低、中、高剂量组分别灌胃给予1.89,3.78,7.56 g/(kg·d)的复方生脉成骨胶囊溶液,模型组灌胃给予等量生理盐水,连续给药8周。给药结束后,分别进行股骨头micro-CT扫描、组织学染色、压缩实验、RT-qPCR及Western blot检测。结果与结论:①micro-CT扫描显示,与空白组比较,模型组大鼠骨小梁体积分数、骨小梁数量及骨小梁厚度减少(P<0.05),骨小梁离散度增加(P<0.05);与模型组比较,中药低、中、高剂量组骨小梁体积分数、骨小梁数量及骨小梁厚度增加(P<0.05),骨小梁离散度减少(P<0.05),且呈剂量依赖性。②苏木精-伊红染色显示,与模型组比较,中药低、中、高剂量组空骨陷窝率减少(P<0.05),且呈剂量依赖性;免疫组化染色显示,与空白组比较,模型组岩藻糖基转移酶8、Runx2、骨形态发生蛋白2的蛋白表达降低(P<0.05);与模型组比较,中药低、中、高剂量组岩藻糖基转移酶8、Runx2、骨形态发生蛋白2的蛋白表达升高(P<0.05),且呈剂量依赖性。③压缩实验显示,与模型组相比,中药低、中、高剂量组股骨头最大载荷及弹性模量升高(P<0.05),且呈剂量依赖性;④RT-qPCR及Western blot检测显示,与空白组相比,模型组岩藻糖基转移酶8、Runx2、碱性磷酸酶、骨钙素、成骨细胞特异性转录因子及骨形态发生蛋白2的mRNA与蛋白表达降低(P<0.05);与模型组相比,中药低、中、高剂量组上述指标的mRNA与蛋白表达升高(P<0.05),且呈剂量依赖性。与空白组比较,模型组Wnt2、低密度脂蛋白受体相关蛋白5及β-连环蛋白的mRNA与蛋白表达降低(P<0.05),糖原合成酶激酶3β的mRNA与蛋白表达升高(P<0.05);与模型组比较,中药低、中、高剂量组Wnt2、低密度脂蛋白受体相关蛋白5及β-连环蛋白的mRNA与蛋白表达升高(P<0.05),糖原合成酶激酶3β的mRNA与蛋白表达降低(P<0.05),且呈剂量依赖性。⑤结果表明,复方生脉成骨胶囊治疗激素性股骨头坏死的机制可能是通过上调岩藻糖基转移酶8表达来激活Wnt/β-catenin信号通路,促进骨形成。

复方鹿茸健骨胶囊治疗老年性骨质疏松的网络药理学与分子对接机制研究

通过网络药理学来预测复方鹿茸健骨胶囊(CLJC)治疗老年性骨质疏松(Senile Osteoporosis,SOP)的作用机制。通过中药系统药理学成分分析平台(BATMAN-TCM)、TCMID数据库、中国知网、PubMed和Web of Science等途径查阅相关文献,中药系统药理学数据库(TCMSP)检索CLJC的主要活性成分,ADME功能以及Uniprot数据库检索筛选CLJC的主要活性成分靶点;通过GeneCards、在线人类孟德尔遗传数据库(OMIM)、疾病相关的基因与突变位点数据库(DisGeNET)检索SOP主要作用靶点;通过Venny2.1.0软件对药物靶点与疾病靶点取交集,两者交集即为CLJC治疗SOP潜在靶点;用STRING数据库分析蛋白质-蛋白质相互作用(PPI),并且构建PPI网络图;用Metascape数据库进行基因本体(GO)和京都基因与基因组百科全书(KEGG)富集分析,并通过Cytoscape 3.9.2软件构建“药物成分-靶点-疾病-通路”网络图;最后,通过Auto Dock Tools 1.5.7软件将核心活性成分与核心靶点进行分子对接,并进一步验证CLJC治疗SOP以及网络药理学所得出的结论。CLJC共筛选到89种活性成分,相对应的药物靶点有463个;SOP共筛选到972个疾病靶点;CLJC与SOP共有81个靶点,核心靶点有AKT1、TP53、CTNNB1、SRC、RXRA、ITGB3、SP1、MMP3、TNF、MMP9、MMP2、TGFB1、PPARG、FOS、IGF2、VEGFA和IL10等;GO分析显示,BP有激素反应(Response to hormone)、肽反应(Response to peptide)、细胞对氮化合物的反应(Cellular response to nitrogen compound)等;MF有信号受体调节器活性(Signaling receptor regulator activity)、信号受体激活器活性(Signaling receptor activator activity)、受体配体活性(Receptor ligand activity)等;CC有隔膜筏(Membrane raft)、膜微结构域(Membrane microdomain)、质膜筏(Plasma membrane raft)等;KEGG富集分析共得到164条通路,主要有癌症通路(Pathways in cancer)、MAPK信号通路(MAPK signaling pathway)、癌症蛋白聚糖(Proteoglycans in cancer)以及脂质和动脉粥样硬化(Lipid and atherosclerosis)等;分子对接验证核心活性成分与核心靶点都表现出良好的对接活性。本研究证实了CLJC中的quercetin成分与AKT1和TP53靶蛋白相互作用,通过Pathways in cancer、MAPK signaling pathway等信号通路多成分、多靶点、多通路治疗SOP。

中药复方基于Wnt/β-catenin信号通路调控糖尿病肾病研究进展

糖尿病肾病是糖尿病最常见的微血管并发症之一,也是造成终末期肾病的主要原因。Wnt/β-catenin信号通路与糖尿病肾病肾小管间质纤维化密切相关,主要通过足细胞、肾小球系膜细胞、肾小管上皮细胞等来改善糖尿病肾病。中药复方基于调控Wnt/β-catenin信号通路来改善肾脏病变及纤维化,保护肾脏功能,进而延缓病程进展,在治疗中发挥激活自噬、减少炎症反应及减弱氧化应激等作用。目前,关于中药复方基于Wnt/β-catenin信号通路的研究仍存在以下不足之处:(1)在中药复方的研究中,能够得出中药复方可通过Wnt/β-catenin信号通路发挥作用,但由于中药复方成份复杂多样,大多数仅仅发现相关性,而没有分析其具体的活性成分;(2)Wnt/β-catenin信号通路的相关研究并未深入探索该信号通路在肾纤维化中的作用机制;(3)目前关于中医药的大部分实验为动物体内实验,缺乏体外细胞的相关实验探究。今后,需加强对中药复方活性成分的研究,并开展更多的体外细胞实验,进行深层次的作用机制及靶点研究。

复方玄驹胶囊治疗反复胚胎种植失败患者的临床效果及对子宫内膜的影响

目的探讨复方玄驹胶囊治疗反复胚胎种植失败(RIF)患者的临床效果及对子宫内膜容受性的影响。方法选取在本院生殖医学中心行体外受精-胚胎移植(IVF-ET)治疗,反复种植失败后经中医辨证属肾阳虚型,并拟再次行胚胎移植的116例患者,将其随机分为治疗组(55例)和对照组(61例)。治疗组采用复方玄驹胶囊联合人工周期内膜准备治疗,对照组采用人工周期内膜准备治疗。比较两组的治疗效果。结果治疗组的雌二醇(E_(2))水平及子宫内膜厚度高于对照组,差异具有统计学意义(P<0.05);两组的孕激素(P)水平及子宫内膜分型比较,差异无统计学意义(P>0.05)。两组的胚胎着床率、临床妊娠率、流产率及异位妊娠率比较,差异无统计学意义(P>0.05);治疗组的活产率高于对照组(P<0.05)。结论复方玄驹胶囊能够显著改善RIF患者的子宫内膜容受性指标,如E2和子宫内膜厚度,同时能使活产率提高。

HPLC-ELSD法测定硫酸庆大霉素碳酸铋胶囊中庆大霉素C组分及有关物质含量

目的为硫酸庆大霉素碳酸铋胶囊中庆大霉素C组分及有关物质建立质控方法。方法采用HPLC-ELSD方法,色谱柱:GRACEApollo C18柱(250 mm×4.6 mm,5μm);流动相:0.2 mol/L三氟乙酸溶液-甲醇(96:4,V/V),流速0.6 mL/min;柱温30℃;进样量20μL;Waters低温分流型蒸发光散射检测器,载气流量40 psi,漂移管温度55℃。结果所建方法通过方法学验证,庆大霉素C组分与各杂质间分离完全,庆大霉素、西索米星和小诺霉素分别在0.5~6 mg/mL、25~100μg/mL和25~100μg/mL的浓度范围内,各浓度的对数值与对应色谱峰面积的对数值呈现出良好的线性。采用所建方法对市售16家生产企业43批次硫酸庆大霉素碳酸铋胶囊样品进行测定,获得该制剂产品中各组分及有关物质的数据。结论所建方法是在中国药典方法基础上优化并验证适用于硫酸庆大霉素碳酸铋胶囊C组分及有关物质的含量测定,方法简便准确,专属性强,稳定性好。由获得的实验数据可知,该复方制剂中C组分及有关物质的含量在各厂家间或同厂家不同批次间差异显著,可能存在影响用药安全的潜在隐患,建议在该剂型质量标准中增加相关质控项。